Dimensional Fund Advisors LP Has $78.52 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Dimensional Fund Advisors LP increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 333,661 shares of the biopharmaceutical company's stock after acquiring an additional 32,272 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.26% of Alnylam Pharmaceuticals worth $78,520,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Trust Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 14.8% during the 4th quarter. First Trust Advisors LP now owns 327,782 shares of the biopharmaceutical company's stock valued at $77,130,000 after buying an additional 42,211 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $710,000. CANADA LIFE ASSURANCE Co grew its holdings in Alnylam Pharmaceuticals by 11.9% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 76,919 shares of the biopharmaceutical company's stock worth $18,087,000 after acquiring an additional 8,206 shares in the last quarter. Marshall Wace LLP increased its position in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after purchasing an additional 315,182 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 97,200.0% in the 4th quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company's stock valued at $229,000 after purchasing an additional 972 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ALNY shares. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a report on Friday. Royal Bank of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Finally, William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $319.17.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock valued at $1,875,627 over the last ninety days. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $4.26 during mid-day trading on Friday, hitting $259.39. 729,702 shares of the stock traded hands, compared to its average volume of 885,109. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company's 50-day simple moving average is $248.21 and its 200-day simple moving average is $255.31. The firm has a market cap of $33.74 billion, a price-to-earnings ratio of -119.53 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the previous year, the business posted ($0.16) EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.